secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001193125-24-163498
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma prices $107.5M public offering of 5M shares at $17.50, plus pre-funded warrants
--------------------------------------------------------------------------------

- Offering: 5,000,000 ordinary shares at $17.50/share plus 1,142,857 pre-funded warrants at $17.499 each.
- Gross proceeds expected to be approximately $107.5 million before underwriting discounts and expenses.
- Underwriters granted a 30-day option to purchase up to an additional 921,428 ordinary shares.
- Closing expected on June 20, 2024, subject to customary conditions.
- TD Cowen and Guggenheim Securities are joint book-running managers; Oppenheimer & Co. is lead manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524163498/0001193125-24-163498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524163498/d854991d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-163498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer